Tagged with korea

Korea Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides her assessment of the impact of the merger. She also comments on Syneos Health’s MoU with KoNECT (Korea National Enterprise…

Korea SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview, Jeong Woo Cho PhD, CEO & president of SK Biopharmaceuticals and SK Life Science, provides an overview of the current…

Korea Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains his strategy to expand into the East Asian market and provides his assessment on how established Korean pharmaceutical companies can…

Korea Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools, Bioneer’s globally distributed platform of molecular diagnostics, and its novel next-generation RNAi therapeutics platform SAMiRNA TM. Dr Park also comments…

Korea The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated an entrepreneurial approach into the organization and assesses the future of Korea as an R&D powerhouse.   I have always…

Korea Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his activities and achievements after passing the halfway mark of his two-year mandate at the helm of the organization. He also…

Korea This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The new process will tighten control on raw drug materials, expand patient compensation for side-effects, and prepare review systems for advanced…

Korea The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are calling for even greater governmental support for what is still a tightly regulated sector facing pressures over pricing, exacerbated partly…

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…

Korea An outline of the geographical distribution of clinical trial sites in South Korea. 184 medical institutions were designated by the Korean government as qualified clinical trial sites in December 2016, 57 of which were in the capital, Seoul.   Within Asia-Pacific, South Korea was the nation with the highest number…

Samsung Biologics It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building a series of progressively larger, more advanced facilities, culminating in its 180,000L “Dream Plant.” This facility, the largest single plant…

Korea Examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Here, Eugene Kim, Seoul office leader of executive search firm Egon Zehnder outlines the new profile he looks for in potential candidates for country manager positions in South…